Complement Inhibition in Geographic Atrophy: Clinical Evidence for Pegcetacoplan and Avacincaptad Pegol. [PDF]
Orozco Loaiza G +3 more
europepmc +1 more source
Direct Switch From Iptacopan to Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria. [PDF]
Latyshev V +3 more
europepmc +1 more source
Reply to Letter: "Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring" by Saccà and Pelto Regarding "Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab". [PDF]
Gerischer L +3 more
europepmc +1 more source
Complement Dysregulation in Kidney Diseases: Mechanisms, Biomarkers, and Emerging Targeted Therapies. [PDF]
Jesiołowski P +3 more
europepmc +1 more source
The Complement System in the Setting of Critical Illness-A Narrative Review. [PDF]
Ampelakiotou K +5 more
europepmc +1 more source
Complement activation in kidney transplantation. [PDF]
Kanbay M +7 more
europepmc +1 more source
Overexpression of key complement regulators in glioblastoma. [PDF]
Blomberg L +4 more
europepmc +1 more source
New Anticomplement Drugs in Nephrology: Mechanism and Indication.
Macciò L +5 more
europepmc +1 more source
Efficacy and Safety of Crovalimab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Meta-Analysis. [PDF]
Javaid H +11 more
europepmc +1 more source
Epidemiology and care management of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a real-world setting in France: Description from the French National Hospitalization Database. [PDF]
Peffault de Latour R +7 more
europepmc +1 more source

